Since 1 April 2020, Track Record has profiled 6 companies, which, on average, their share price has risen by 215%. The top 2 companies were Pointerra (ASX:3DP) at 2,4000% and Botanix Pharmaceuticals at 122% as at 1 April 2021. This means the profiled companies outperformed the ASX All Ords by 181% since 1 April 2020.
“I want to suggest to you that Pareto’s Law suggests that the most important thing that you can do is have the discipline to invest with the serially successful. Stop, just the serially successful.”
By simply following this successful industry entrepreneur’s investment in this publicly listed small cap, investors made more than a 100x return on their investment.
Since 1 April 2020, Track Record has profiled 5 companies, which, on average, their share price has risen by 206%. The top 2 companies were Pointerra (ASX:3DP) at 2,150% (21x) and Botanix Pharmaceuticals at 200% (2x) as at 14 December 2020. This means the profiled companies outperformed the ASX All Ords by 175% since 1 April 2020.
I believe intelliHR’s SaaS based operational metrics put it in the 75th percentile when compared to global SaaS companies at its current stage (e.g. Sales and Marketing efficiency (Magic Number), Gross Profit Margin (GPM) and Annual Recurring Revenue (ARR) growth), NPS).
Larger revenues means larger valuations, which results in larger returns for investors. So by investing in successful entrepreneurs, investors can make more money, more often.
He has successfully built 4 companies with a combined value of over AUD$9bn (2 of these successes were in the technology industry).
Billionaire tech entrepreneur, Bevan Slattery, invests AUD2.5m in ASX SaaS startup
Its Annual Recurring Revenue (ARR) has grown from approximately AUD850k to AUD2.36m in the last 12 months (177% Year on Year (YoY) growth) as at 30 June 2020. The company has achieved this growth while achieving cash flow break-even last quarter and maintaining AUD3m in the bank.
Copyright © Track Record